載入中
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
前收盤價
US$1.8352
−US$0.0548 · -2.90%
盤前
US$1.84
+US$0.0048 · +0.26%
10月12日 上午4:00 ET
盤中時間採用ET。市場資料可能有所延遲。
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
日內區間
目前US$1.8352
52週區間
目前US$1.8352
盤中時間採用ET。市場資料可能有所延遲。
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
日內區間
目前US$1.8352
52週區間
目前US$1.8352
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 445.3萬 USD | 531.1萬 USD | 541.5萬 USD | 533.9萬 USD | 1887.14萬 USD |
| 銷貨成本 | 409.1萬 USD | 481.3萬 USD | 480.4萬 USD | 489.3萬 USD | 1589.4萬 USD |
| 毛利 | 36.2萬 USD | 49.8萬 USD | 61.1萬 USD | 44.6萬 USD | 297.74萬 USD |
| 研究與開發 | 78.8萬 USD | 102.3萬 USD | 149.1萬 USD | 158.4萬 USD | 181.24萬 USD |
| 銷售、一般及管理費用 | 489.4萬 USD | 461.2萬 USD | 548.7萬 USD | 608.5萬 USD | 569.9萬 USD |
| 營業費用 | 568.2萬 USD | 563.5萬 USD | 697.8萬 USD | 766.9萬 USD | 751.14萬 USD |
| 利息收入 | 123.3萬 USD | 16.5萬 USD | 43.1萬 USD | 13.3萬 USD | 2.7萬 USD |
| 折舊和攤銷 | 42.1萬 USD | 40萬 USD | 37.4萬 USD | 35.1萬 USD | 59.48萬 USD |
| 營業利益 | −532萬 USD | −513.7萬 USD | −636.7萬 USD | −722.3萬 USD | −453.4萬 USD |
| 淨利 | −377.5萬 USD | −497.3萬 USD | −597.8萬 USD | −714萬 USD | −453.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅3項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年4月21日 | 1:8 | — | — |
股票分割 | 1994年11月14日 | 1:2 | — | — |
股票分割 | 1980年12月15日 | 3:2 | — | — |
股票分割 | 1980年6月30日 | 5:4 | — | — |
已生效 2025年4月21日
1:8
已生效 1994年11月14日
1:2
已生效 1980年12月15日
3:2
已生效 1980年6月30日
5:4
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
